All In Biotech

Drug Trial Radar · NCT00820885

A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Sep 6, 2006

Primary completion

Apr 23, 2007

Study completion Apr 23, 2007

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Jan 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study was to study the safety and tolerability of teduglutide following a once or possibly twice daily subcutaneous injection for eight consecutive days in healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide following a once or possibly twice daily injection for eight consecutive days in healthy subjects.

Conditions

  • Pharmacokinetics and Safety of Elevated Doses

Interventions

  • teduglutideDrug

    subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

  • teduglutideDrug

    Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

  • tedguglutideDrug

    lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Each dose arm is safeTime frame: Within 1 week of each cohort completion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwest Kinetics

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.